SHAREHOLDER ALERT: AHCO ITRM KPLT: Vincent Wong Law Firms Remind Investors of Important Class Action Deadlines | 2021-09-26 | Press Releases
NEW YORK, NY / ACCESSWIRE / September 26, 2021 / Vincent Wong’s law firms announce that class actions have been initiated on behalf of certain shareholders of the following companies. If you have suffered harm, you have until the lead plaintiff deadline to request that the court appoint you lead plaintiff. There will be no obligation or cost to you.
AdaptHealth Corp. f / k / a DFB Healthcare Acquisitions Corp. (NASDAQ: AHCO)
If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/adapthealth-corp-fka-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=19870&wire=1
Lead applicant’s deadline: September 27, 2021
Class period: November 11, 2019 – July 16, 2021
The allegations against AHCO include that: (i) AdaptHealth had distorted its organic growth trajectory by retroactively inflating past organic growth figures without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) as a result, the Company had substantially overestimated its financial outlook; and (iii) accordingly, the Company’s public statements were materially false and misleading at all material times.
Iterum Therapeutics Plc (NASDAQ: ITRM)
If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19870&wire=1
Lead Applicant Deadline: October 4, 2021
Class period: November 30, 2020 – July 23, 2021
Claims against ITRM include the following: (i) the new drug application sulopenem (“NDA”) lacked sufficient data to support the approval of treatment for adult women with urinary tract infections caused by urinary tract infections. sensitive microorganisms designated, proven or strongly suspected to be non-sensitive to a quinolone; (ii) therefore, the Food and Drug Administration was unlikely to approve sulopenem NDA in its current form; (iii) the defendants downplayed the seriousness of the problems and shortcomings associated with the NDA of sulopenem; and (iv) accordingly, the Company’s public statements were materially false and misleading at all material times.
Katapult Holdings, Inc. (NASDAQ: KPLT)
If you have suffered a claim, contact us at:https://www.wongesq.com/pslra-1/katapult-holdings-inc-loss-submission-form?prid=19870&wire=1
Lead Applicant Deadline: October 26, 2021
Course period: December 18, 2020 – August 10, 2021
Allegations against KPLT include that: (1) Katapult was experiencing a decline in e-commerce retail sales and consumer spending, (2) despite Katapult’s claims that this was a clear and compelling value proposition for consumers and merchants, transforming the way unprivileged consumers buy essential commodities and enabling merchants to access this underserved segment, Katapult lacked visibility into the future purchasing behavior of its consumers; and (3) as a result of the foregoing, the Defendants’ positive statements regarding the business, operations and prospects of the Company were substantially false and misleading and / or lacked reasonable basis.
For more information, contact Vincent Wong, Esq. either by email [email protected] or by phone at 212.425.1140.
Vincent Wong, Esq. is an experienced lawyer who has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Lawyer advertising. Past results do not guarantee similar results.
Vincent Wong, Esq.
39 Broadway East
New York, New York 10002
Email: [email protected]
THE SOURCE: Vincent Wong’s law firms
See the source version on accesswire.com: